Hemostasis Today

June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Joep Schellens: Influence of Dexamethasone and Tocilizumab on Fibrinolysis in COVID-19
Jun 2, 2026, 15:20

Joep Schellens: Influence of Dexamethasone and Tocilizumab on Fibrinolysis in COVID-19

Joep Schellens, PhD-student at Maastricht UMC+, shared on LinkedIn about a recent article he and his colleagues co-authored, published in Thrombosis Research, adding:

”I’m excited to share my article, ‘Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the Maastricht cohort’, has been published in Thrombosis Research.

This publication outlines the influence of dexamethasone and tocilizumab treatment on coagulation and fibrinolysis in COVID-19 ICU patients.

Many thanks to my co-authors for their valuable contributions to this work!”

Title: Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the MaastrICCht cohort

Authors: Joep Schellens, Magdolna Nagy, Anne-Marije Hulshof, Frank van Rosmalen, René van Oerle, Thijs T.W. van Herpt, Teba Alnima, Mark M.G. Mulder, Dave Hellenbrand, Hugo ten Cate, Rob G.H. Driessen, Jan-Willem E.M. Sels, Iwan C.C. van der Horst, Yvonne M.C. Henskens, Bas C.T. van Bussel, Henri M.H. Spronk on behalf of the Dutch Covid and Thrombosis Coalition

Joep Schellens: Influence of Dexamethasone and Tocilizumab on Fibrinolysis in COVID-19

Stay updated on all scientific advances with Hemostasis Today.